APA (7th ed.) Citation

N, H., C, A., C, K., A, J., JM, M., E, C., . . . F, R. (2022). Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial. AIDS research and therapy, 19(1), 4. https://doi.org/10.1186/s12981-022-00428-5

Chicago Style (17th ed.) Citation

N, Hall, et al. "Raltegravir 1200 mg Once Daily as Maintenance Therapy in Virologically Suppressed HIV-1 Infected Adults: QDISS Open-label Trial." AIDS Research and Therapy 19, no. 1 (2022): 4. https://doi.org/10.1186/s12981-022-00428-5.

MLA (9th ed.) Citation

N, Hall, et al. "Raltegravir 1200 mg Once Daily as Maintenance Therapy in Virologically Suppressed HIV-1 Infected Adults: QDISS Open-label Trial." AIDS Research and Therapy, vol. 19, no. 1, 2022, p. 4, https://doi.org/10.1186/s12981-022-00428-5.